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3-(1h-benzimidazol-2-yl)-1,2,2- trimethylcyclopentancarboxylic acid (C7070) is a novel synthetic imidazoline 
receptor agonist - potential antidiabetic agent. This study aimed to obtain the pharmacokinetic profiles in rats.  
Additionally, an HPLC MS/MS method was developed and validated to quantify C7070 in rat plasma. The 
pharmacokinetic profiles of intragastric and intravenous administration routes at singles doses of 50 mg/kg, 
were studied in rats. The elimination half-life of intravenously administered C7070 was approximately 154.1 
min. The maximum plasma level of C7070 was reached approximately 170 min (2.8 h) after intragastric 
administration, with a Cmax value of 17.6 μg/mL and an AUC (o-t) value of 6964 μg*min
-1
/mL; the oral 
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High blood pressure, or hypertension, is a condition that 
often affects people with type 2 diabetes. It is widely assumed 
that obesity, a high-fat, high-sodium diet, and inactivity have led 
to a rise in both conditions. Type 2 diabetes is a major cause of 
morbidity and an important risk factor for cardiovascular disease, 
cerebral infarction, blindness, and kidney failure. The prevalence 
of type 2 diabetes is increasing worldwide, and it is estimated 
that more than 366 million people will be affected by 2030 
(Brigand et al., 1997). Pharmacologic treatment of many type 2 
diabetic patients requires separate agents for treating 
hyperglycemia, and hypertension. This results in patients having 
to take multiple medications, which negatively impact patient 
compliance and increases the risk for drug interaction. In 
response to this growing health care problem, compounds the at 
have the ability to counter both hyperglycemia and hypertension 
would positively impact compliance and be an asset to patients            
.   
    
 














(Mourtada et al., 1998). At present, to solve such problems is to 
use a prospective direction imidazoline receptor agonists (Brigand 
et al., 1999). 
Pharmacologic criteria have defined three main types of 
imidazoline receptors: the I1 subtype is labeled by [
3
H] clonidine 
and the I2 subtype is labeled by [
3
H] idazoxan. A third 
pharmacologically distinct entity, the I3 subtype, is found in the 
pancreas and is involved in regulation of insulin secretion. Several 
studies have shown that compounds containing the imidazoline 
moiety are potent stimulators of insulin secretion from pancreatic β 
-cells [1-5]. Development and study of imidazoline receptor 
agonist is of great importance in the treatment of type 2 diabetes 
and hypertension. Preparation of the pharmacokinetic profiles for 
various routes of administration in animals is an important step in 
developing drugs (Efanov et al., 2001). 
 
MATERIALS AND METHODS 
 
Chemicals, reagents and animals 
We used the following reagents: C7070 ("VladMiVa", 
RF, Belgorod), fabomotizole - IS (Sigma), formic acid (Panreac), 
аmmonium acetate (Panreac), methanol (Merk), acetonitrile  
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gradient grade (Merk), deionized water of system «Gene Pure» 
(Thermo Scientific, USA). 
We used the rats Wistar. The animals were housed in the 
Center of preclinical and clinical studies support the cycle 
day/night, temperature of 25±2 
o
C and relative humidity 50±5 %. 
The rats were fasted overnight (approximately 12 h) before each 
experiment. The basic rules of maintenance and care meet the 
standards, according to the guide: Guide for the care and use of 




 HPLC Thermo Ultimate 3000  (Thermo Scientific); 
 MS/MS Velos Pro (Thermo Scientific); 
 Pipettes 0.5-10 µL, 10-100 µL, 20-200 µL и 100 –1000 µL 
(Eppendorf); 
 Soft Xcalibur 2.2 Sp1(Thermo Scientific); 
 Ultrasonic bath; 
 HPLC column Zorbax Eclipse XDB-C18 (3.5 μm, 150 х 3.0 
мм + guard cartridge); 




To study the pharmacokinetics of 12 rats were pre-
catheterized in the right jugular vein to sample blood at all-time 
points were taken from the same animal throughout the 
experiment. For the operation intraperitoneal anesthesia used: 10% 
zoletil 2% xylazine = 1: 5, at 70 ul / 100 g body weight. After the 
operation was monitored daily animal health. In the 12 hours 
before the start of the experiment the animals were deprived of 
food, leaving free access to water. On the third day of the study 
drug was administered after catheterization (Olsen et al., 2003).  
For intravenous dosing, test substance is administered a 
bolus of 6 rats in the tail vein as a solution of 50 mg/ml in 
propylene glycol at 50 mg/kg. Blood was collected through the 
catheter in a volume of 0.2 mL polypropylene tubes containing 20 
ul of 5% K3 to enter, at 5, 15, 30, 60, 120, 240, 480, and 1440 
minutes after administration.  
When the substance was administered intragastrically 
dosed with a probe in a solution of 50.0 mg /ml in propylene 
glycol at 50 mg/kg. Blood was collected through the catheter in a 
volume of 0.2 mL polypropylene tubes containing  20 ul of 5% K3 
to input 15, 30, 60, 120, 240, 480, and 1440 minutes after 
administration. Blood plasma was separated by centrifugation at 






Plasma concentrations of С7070 were measured by an 
Thermo Ultimate 3000 (Thermo Scientific) HPLC system 
equipped with - MS/MS detector Velos Pro (Thermo Scientific). 
Separations were carried out on an Exlipse XDB C18 column (150 
mm×3.0 mm, 3.5 μm) with a guard cartridge. The mobile phase 
consisted of 5 mM ammonium acetate + 0,1 % formic acid (A), 
methanol (B), acetonitrile (C) in gradient mode (0→ 5 min:     A - 
80 %, B - 0 %, C - 20 %; 5.0 → 8.5 min: A - 65 %, B - 10 %, C- 
10 %; 8.5→9.0 min: A - 20 %, B - 10 %, C- 70 %;  9.0-11.0 min A 
- 20 %, B - 10 %,  C- 70 %; 11.0→11,1 min A - 80 %, B - 0 %,  C- 
20 %; 11.1→12.0 min A - 80 %, B - 0 %,  C- 20 %)  at a flow-rate 
of 0.4 mL/min. The parameters of the detector: ESI positive mode, 
conversion masses for C7070 272.35→255.15; for IS 
307.41→114.0 source temperature 300 
o
C, voltage at the source 3 
kV, remaining parameters in accordance with an automatic 
optimization tool. The temperature of the samples – 4.0 
o
C, 
column – 40.0 
o
C, injection volume – 2.0 µL. Before the research 
method has been validated [6-7]. Retention time C7070 – about 
4.7 min, IS  – about 8.5 min 
 
Concentration determination  
The concentration was determined from a linear standard 
curve ranging from 3.9 ng to 20 mg per/ml of plasma. For this 
purpose, standard solutions were prepared solutions and solutions 
QC. Preparation of the solutions included the following steps of: 
100 ul of plasma were placed in vials "eppendorf" 1.5 ml, was 
added 100 ul of IS solution was stirred, 100 ul of acetonitrile was 
added and extracted in an ultrasonic bath for 3 minutes. The 
samples were then frozen for 20 minutes at – 70 °C. After thawing, 
samples were centrifuged at 13,000 rpm at 4 °C for 25 minutes. 
The supernatant was carefully decanted into vials for 
chromatography and analyzed. Test solutions were prepared 
similarly to standard solutions and solutions QC (Committee for 
Medicinal Products for Human Use. 2011). 
 
Data analysis 
Results obtained from the HPLC analyses were plotted as 
concentration–time curves for plasma. Pharmacokinetic analysis   
was performed using the Microsoft Office Excel 2010   software. 
The mean area under the curve (AUC) was calculated by the 
trapezoidal method. The maximum concentration (Cmax) and the 
time to reach peak concentration (tmax) were the observed values. 
Results are presented as mean values ±S.D. 
 
RESULTS AND DISCUSSION 
The mean plasma levels of C7070 following a single dose 
of intragastric and intravenous administration are shown in Fig. 1. 
The plasma drug concentration data and the PK parameters are 
presented in Table 1. 
We studied the pharmacokinetics of the agent C7070 
imidazoline receptor agonist, a potential anti-diabetic 
drug. Pharmacokinetics and bioavailability of C7070 was studied 
in blood plasma of Wistar rats after a single intravenous and 
intragastric administration of 50 mg/kg. C7070 content in the 
samples was analyzed by HPLC with MS/MS detection. 
The results showed that a reduction in the plasma 
concentration C7070 blood test animals is rapid and biexponential 
character. C7070 pharmacokinetic profile in the blood plasma after 
intravenous and intragastric routes of administration have similar           
. 
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Table 1: Plasma pharmacokinetic parameters of С7070 after intravenous and 
intragastric administration at a dose of 50 mg/kg (mean ± S.D, n=6). 
 
Parameter intragastric intravenous 
tmax (min) 170.0±79.8 - 
Cmax (μg/mL) 17.6±1.4 33.6±40.5 
t1/2 (min) 225.2±12.4 154.1± 5.1 
MRT (min) 325.0±17.9 222.3±7.3 
AUC0−t (μg*min/mL) 6592.7±577.3 37857.7±3180.1 
Bioavailability (%) 18.1 - 
 
 
Fig. 1: Average C7070 concentration in plasma as a function of time after 
intravenous and intragastric administration at a dose of 50 mg/kg (mean±S.D., 
n=6). 
 
dynamics changes. The mean time of absorption (MAT) was 102.7 
minutes. Bioavailability C7070 at intragastric dosing was 18.1%. 
C7070 is slowly absorbed, tmax was 170 minutes. However, the 
concentration of the substance for a long time observed t1/ 2 -225 
minutes in rat plasma. This allows to conclude that the positive 
properties of  C7070 as a potential anti-diabetic agents. Receiving 
single dose provides a prolonged therapeutic effect. The first phase 
(absorption) is smooth in nature, excluding the shock effect. The 
second phase (distribution) is a fast character, reflecting the rapid 
distribution of C7070 in rats. The third phase (elimination) is slow 
in nature, indicating the length of stay organism rats. C7070 has all 
the properties of the potential anti-diabetic drug, and will continue 
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